China · Delayed Price · Currency is CNY Getein Biotech Statistics
Total Valuation
Getein Biotech has a market cap or net worth of CNY 4.69 billion. The enterprise value is 3.46 billion.
| Market Cap | 4.69B |
| Enterprise Value | 3.46B |
Important Dates
The last earnings date was Thursday, August 27, 2026.
| Earnings Date | Aug 27, 2026 |
| Ex-Dividend Date | Jun 18, 2026 |
Share Statistics
Getein Biotech has 507.15 million shares outstanding. The number of shares has decreased by -3.08% in one year.
| Current Share Class | 507.15M |
| Shares Outstanding | 507.15M |
| Shares Change (YoY) | -3.08% |
| Shares Change (QoQ) | +1.27% |
| Owned by Insiders (%) | 40.61% |
| Owned by Institutions (%) | 4.13% |
| Float | 284.30M |
Valuation Ratios
The trailing PE ratio is 15.57.
| PE Ratio | 15.57 |
| Forward PE | n/a |
| PS Ratio | 4.29 |
| PB Ratio | 1.54 |
| P/TBV Ratio | 1.70 |
| P/FCF Ratio | 15.10 |
| P/OCF Ratio | 10.81 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.14, with an EV/FCF ratio of 11.14.
| EV / Earnings | 11.68 |
| EV / Sales | 3.16 |
| EV / EBITDA | 10.14 |
| EV / EBIT | 13.67 |
| EV / FCF | 11.14 |
Financial Position
The company has a current ratio of 3.76, with a Debt / Equity ratio of 0.11.
| Current Ratio | 3.76 |
| Quick Ratio | 3.03 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | 1.00 |
| Debt / FCF | 1.10 |
| Interest Coverage | 20.93 |
Financial Efficiency
Return on equity (ROE) is 10.02% and return on invested capital (ROIC) is 12.50%.
| Return on Equity (ROE) | 10.02% |
| Return on Assets (ROA) | 4.12% |
| Return on Invested Capital (ROIC) | 12.50% |
| Return on Capital Employed (ROCE) | 8.19% |
| Weighted Average Cost of Capital (WACC) | 3.94% |
| Revenue Per Employee | 631,482 |
| Profits Per Employee | 170,885 |
| Employee Count | 1,733 |
| Asset Turnover | 0.28 |
| Inventory Turnover | 1.92 |
Taxes
In the past 12 months, Getein Biotech has paid 29.03 million in taxes.
| Income Tax | 29.03M |
| Effective Tax Rate | 9.02% |
Stock Price Statistics
The stock price has increased by +10.75% in the last 52 weeks. The beta is -0.05, so Getein Biotech's price volatility has been lower than the market average.
| Beta (5Y) | -0.05 |
| 52-Week Price Change | +10.75% |
| 50-Day Moving Average | 8.88 |
| 200-Day Moving Average | 8.85 |
| Relative Strength Index (RSI) | 51.37 |
| Average Volume (20 Days) | 10,991,693 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Getein Biotech had revenue of CNY 1.09 billion and earned 296.14 million in profits. Earnings per share was 0.59.
| Revenue | 1.09B |
| Gross Profit | 740.21M |
| Operating Income | 253.01M |
| Pretax Income | 321.91M |
| Net Income | 296.14M |
| EBITDA | 336.75M |
| EBIT | 253.01M |
| Earnings Per Share (EPS) | 0.59 |
Balance Sheet
The company has 1.68 billion in cash and 341.53 million in debt, with a net cash position of 1.34 billion or 2.64 per share.
| Cash & Cash Equivalents | 1.68B |
| Total Debt | 341.53M |
| Net Cash | 1.34B |
| Net Cash Per Share | 2.64 |
| Equity (Book Value) | 3.05B |
| Book Value Per Share | 5.71 |
| Working Capital | 1.88B |
Cash Flow
In the last 12 months, operating cash flow was 434.02 million and capital expenditures -123.43 million, giving a free cash flow of 310.58 million.
| Operating Cash Flow | 434.02M |
| Capital Expenditures | -123.43M |
| Depreciation & Amortization | 83.74M |
| Net Borrowing | -348.43M |
| Free Cash Flow | 310.58M |
| FCF Per Share | 0.61 |
Margins
Gross margin is 67.64%, with operating and profit margins of 23.12% and 27.06%.
| Gross Margin | 67.64% |
| Operating Margin | 23.12% |
| Pretax Margin | 29.41% |
| Profit Margin | 27.06% |
| EBITDA Margin | 30.77% |
| EBIT Margin | 23.12% |
| FCF Margin | 28.38% |
Dividends & Yields
This stock pays an annual dividend of 0.30, which amounts to a dividend yield of 3.24%.
| Dividend Per Share | 0.30 |
| Dividend Yield | 3.24% |
| Dividend Growth (YoY) | -16.67% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 25.24% |
| Buyback Yield | 3.08% |
| Shareholder Yield | 4.67% |
| Earnings Yield | 6.31% |
| FCF Yield | 6.62% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on June 8, 2022. It was a forward split with a ratio of 1.4.
| Last Split Date | Jun 8, 2022 |
| Split Type | Forward |
| Split Ratio | 1.4 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 7 |